SARS-CoV-2 rapid antigen tests provide benefits for epidemic
control - observations from Austrian schools

J 2022

SARS-CoV-2 rapid antigen tests provide benefits for epidemic control - observations from Austrian schools

POLECHOVA, Jitka, Kory D JOHNSON, Pavel PAYNE, Alex CROZIER, Mathias BEIGLBOECK et. al.

Základní údaje

Originální název

SARS-CoV-2 rapid antigen tests provide benefits for epidemic control - observations from Austrian schools

Autoři

POLECHOVA, Jitka, Kory D JOHNSON, Pavel PAYNE (203 Česká republika, domácí), Alex CROZIER, Mathias BEIGLBOECK, Pavel PLEVKA (203 Česká republika, garant, domácí) a Eva SCHERNHAMMER

Vydání

Journal of clinical epidemiology, New York, Elsevier, 2022, 0895-4356

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10607 Virology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.200

Kód RIV

RIV/00216224:14740/22:00128814

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1016/j.jclinepi.2022.01.002

UT WoS

000912936400001

Klíčová slova anglicky

COVID-19; SARS-CoV-2; Lateral flow device; Public health; Repeat testing; Large-scale testing

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 6. 3. 2023 18:04, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Objective: This paper motivates and justifies the use of antigen tests for epidemic control as distinct from a diagnostic test. Study Design and Setting: We discuss the relative advantages of antigen and PCR tests, summarizing evidence from both the literature as well as Austrian schools, which conducted frequent, mass rapid antigen testing during the spring of 2021. While our report on testing predates Delta, we have updated the review with recent data on viral loads in breakthrough infections and more information about testing efficacy, especially in children. Results: Rapid antigen tests detect proteins at the surface of virus particles, identifying the disease during its infectious phase. In contrast, PCR tests detect viral genomes: they can thus diagnose COVID-19 before the infectious phase but also react to remnants of the virus genome, even weeks after live virus ceases to be detectable in the respiratory tract. Furthermore, the logistics for administering the tests are different. Large-scale rapid antigen testing in Austrian schools showed low false-positive rates along with an approximately 10% lower effective reproduction number in the tested cohort. Conclusion: Using antigen tests at least 2-3 times per week could become a powerful tool to suppress the COVID-19 pandemic. (c) 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Citovat

POLECHOVA, Jitka, Kory D JOHNSON, Pavel PAYNE, Alex CROZIER, Mathias BEIGLBOECK, Pavel PLEVKA a Eva SCHERNHAMMER. SARS-CoV-2 rapid antigen tests provide benefits for epidemic control - observations from Austrian schools. Journal of clinical epidemiology. New York: Elsevier, 2022, roč. 145, MAY, s. 14-19. ISSN 0895-4356. Dostupné z: https://dx.doi.org/10.1016/j.jclinepi.2022.01.002.

@article{2264628,
   author = {Polechova, Jitka and Johnson, Kory D and Payne, Pavel and Crozier, Alex and Beiglboeck, Mathias and Plevka, Pavel and Schernhammer, Eva},
   article_location = {New York},
   article_number = {MAY},
   doi = {http://dx.doi.org/10.1016/j.jclinepi.2022.01.002},
   keywords = {COVID-19; SARS-CoV-2; Lateral flow device; Public health; Repeat testing; Large-scale testing},
   language = {eng},
   issn = {0895-4356},
   journal = {Journal of clinical epidemiology},
   title = {SARS-CoV-2 rapid antigen tests provide benefits for epidemic control - observations from Austrian schools},
   url = {https://www.sciencedirect.com/science/article/pii/S0895435622000087?via%3Dihub},
   volume = {145},
   year = {2022}
}

TY  - JOUR
ID  - 2264628
AU  - Polechova, Jitka - Johnson, Kory D - Payne, Pavel - Crozier, Alex - Beiglboeck, Mathias - Plevka, Pavel - Schernhammer, Eva
PY  - 2022
TI  - SARS-CoV-2 rapid antigen tests provide benefits for epidemic control - observations from Austrian schools
JF  - Journal of clinical epidemiology
VL  - 145
IS  - MAY
SP  - 14-19
EP  - 14-19
PB  - Elsevier
SN  - 08954356
KW  - COVID-19
KW  - SARS-CoV-2
KW  - Lateral flow device
KW  - Public health
KW  - Repeat testing
KW  - Large-scale testing
UR  - https://www.sciencedirect.com/science/article/pii/S0895435622000087?via%3Dihub
N2  - Objective: This paper motivates and justifies the use of antigen tests for epidemic control as distinct from a diagnostic test. Study Design and Setting: We discuss the relative advantages of antigen and PCR tests, summarizing evidence from both the literature as well as Austrian schools, which conducted frequent, mass rapid antigen testing during the spring of 2021. While our report on testing predates Delta, we have updated the review with recent data on viral loads in breakthrough infections and more information about testing efficacy, especially in children. Results: Rapid antigen tests detect proteins at the surface of virus particles, identifying the disease during its infectious phase. In contrast, PCR tests detect viral genomes: they can thus diagnose COVID-19 before the infectious phase but also react to remnants of the virus genome, even weeks after live virus ceases to be detectable in the respiratory tract. Furthermore, the logistics for administering the tests are different. Large-scale rapid antigen testing in Austrian schools showed low false-positive rates along with an approximately 10% lower effective reproduction number in the tested cohort. Conclusion: Using antigen tests at least 2-3 times per week could become a powerful tool to suppress the COVID-19 pandemic. (c) 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
ER  -

POLECHOVA, Jitka, Kory D JOHNSON, Pavel PAYNE, Alex CROZIER, Mathias BEIGLBOECK, Pavel PLEVKA a Eva SCHERNHAMMER. SARS-CoV-2 rapid antigen tests provide benefits for epidemic control - observations from Austrian schools. \textit{Journal of clinical epidemiology}. New York: Elsevier, 2022, roč.~145, MAY, s.~14-19. ISSN~0895-4356. Dostupné z: https://dx.doi.org/10.1016/j.jclinepi.2022.01.002.

Podrobný výpis o publikaci